INTRODUCTION {#s1}
============

It has been known since the 1930\'s that the anterior pituitary gland secretes several hormones which not only stimulate the thyroid, the gonads, and the adrenal cortex, but also regulate various physiologic processes. However, the mechanisms of the control of pituitary function itself were not understood. In the 1950's, G.W. Harris assembled anatomical and physiological evidence suggesting that the hypothalamic portion of the brain secreted neurohormones that traversed the hypophyseal portal vessels to regulate secretion of pituitary hormones \[[@R1]\]. The work to prove Harris\'s neurohormonal theory extended over 30 years, and one of us (A.V.S.) played a major part in this endeavor. The discovery, isolation, structural identification, chemical synthesis, and information gathered from animal and human studies, regarding several of these hypothalamic hormones, established their regulatory function in the process of mediation of release of various anterior pituitary hormones \[[@R2]--[@R12]\].

Hypothalamic hormones are now known to influence growth, reproduction, lactation, metabolism, gastrointestinal function, and the response to stress, by initiating and regulating the hypothalamic-pituitary axis (HPA). This mediation involves a set of endocrine feedback mechanisms that greatly influence reproductive processes and the aforementioned metabolic activities. These regulatory effects are exerted by endocrine hormone ligands binding directly to specific receptors in appropriate target organs. Importantly, the expression of these receptors also extends to organs outside the HPA. Thus, interactions between agonistic and antagonistic hypothalamic hormone ligands and extrapituitary receptors may influence the physiology of host organs or the pathologic progression of a tumor or other lesion \[[@R13]--[@R16]\]. The development of synthetic analogs of hypothalamic hormones such as Luteinizing Hormone Releasing Hormone (LHRH; also called Gonadotropin Releasing Hormone, or GnRH) \[[@R17]\], Growth Hormone Releasing Hormone (GHRH) \[[@R18]\] and others has led to innovative experimental findings and to various clinical applications such as the treatment of benign prostatic hyperplasia \[[@R19]\] and prostate cancer \[[@R20], [@R21]\]. In addition, multiple preclinical and experimental studies have suggested that targeted cytotoxic and radiolabeled peptide conjugates, specific to hypothalamic hormone receptors, can be powerful tools for diagnosis, for primary therapy or, as adjuvants, to treat neoplastic lesions in extrapituitary organs such as breast \[[@R22]--[@R25]\], ovaries, endometrium \[[@R22]\], prostate, colon \[[@R26]\], liver \[[@R27]\] urinary bladder \[[@R28]\] and lung \[[@R29]\]. Moreover, GHRH-agonist-based therapy has recently been shown to serve cardioprotective and regenerative roles in patients with myocardial infarction \[[@R30]--[@R32]\].

GRP belongs to the bombesin-like peptide family, and is not a classical hypothalamic-hypophyseal regulatory hormone since it plays only a perfunctory role in the mediation of pituitary hormone release. However, GRP/bombesin-like immunoreactivity is widely distributed in mammalian brain, especially the hypothalamus, GI tract and in human fetal lung \[[@R33]\].

The expression of hypothalamic hormones and their receptors in the mammalian eye has been previously reported, mainly using rat models and mostly limited to retinal tissue \[[@R34]--[@R39]\]. Somatostatin receptors have been previously described in the human retina and other ocular structures \[[@R40]--[@R43]\] as has TRH, which has also been identified in human retina \[[@R44]\]. However, the presence of other neuropeptides and their receptors has yet to be systematically or extensively described in the multiple sub-portions of ocular anatomy.

With the onset of the transformational medical role that anti-VEGF therapy has exerted in the field of diabetic retinopathy, somatostatin analogs have been presented as a potential therapeutic alternative for these patients \[[@R45]\] as well as for patients with age-related macular degeneration \[[@R46]\]. Further, antagonistic effects of GHRH and cAMP response element-binding-protein analogs have been suggested to mediate reduction of ocular inflammation in animal models \[[@R47]\]. TRH has been indirectly associated with intraocular pressure elevation \[[@R48]\]. To our knowledge, mechanisms for the role of these neuropeptides in ocular physiology and pathology in the human eye remain to be defined. These investigations, of course, would be abetted and would need to be preceded by such a systematic verification of the presence of these neuropeptides and their receptors.

In this study, we used immunofluorescence staining, Western blot analysis, and RT-PCR to comprehensively identify the expression of the following hypothalamic neuropeptide ligands: LHRH, GHRH, TRH, somatostatin, and GRP as well as the presence of their respective receptors (LHRH-R, GHRH-R, TRH-R, SST-R1 and GRP-R) in the various human eye structures. The structures we included are the conjunctival epithelium, corneal epithelium, corneal endothelium, trabecular meshwork, ciliary body muscle, ciliary body non-pigmented epithelium, lens epithelium, retinal nerve fiber layer, neural retina and optic nerve. The presence of these hormones and their receptors in these structures suggests their potential role in human ocular physiology and in the pathogenesis of ocular disease and may also provide molecular-based targets for the treatment of neoplastic and non-neoplastic ophthalmic diseases.

RESULTS {#s2}
=======

Luteinizing hormone releasing hormone and its receptor {#s2_1}
------------------------------------------------------

LHRH (Figure [1](#F1){ref-type="fig"}) and LHRH-R (Figure [2](#F2){ref-type="fig"}) were identified by Immunofluorescence in paraffin-embedded human eyes using anti-LHRH and anti-LHRH-R antibodies.

![Luteinizing hormone releasing hormone (LHRH)](oncotarget-08-66796-g001){#F1}

![Luteinizing hormone releasing hormone receptor (LHRH-R)](oncotarget-08-66796-g002){#F2}

LHRH was found to be expressed in the corneal epithelium (Figure [1A](#F1){ref-type="fig"}), conjunctival epithelium (Figure [1C](#F1){ref-type="fig"}), ciliary body non-pigmented epithelium (Figure [1D](#F1){ref-type="fig"}), ciliary body muscle (Figure [1E](#F1){ref-type="fig"}) trabecular meshwork (Figure [1F](#F1){ref-type="fig"}), optic nerve (Figure [1G](#F1){ref-type="fig"}), neural retina (Figure [1H](#F1){ref-type="fig"}) and lens epithelium (Figure [1I](#F1){ref-type="fig"}). No expression of LHRH was observed in the corneal endothelium (Figure [1B](#F1){ref-type="fig"}). Expression in the corneal epithelium, conjunctival epithelium and lens epithelium was weaker than the expression in the other aforementioned structures. LHRH was found to be diffusely expressed throughout all layers of the neural retina and RPE.

LHRH-R was found to be expressed in the ciliary body non-pigmented epithelium (Figure [2D](#F2){ref-type="fig"}), ciliary body muscle (Figure [2E](#F2){ref-type="fig"}), trabecular meshwork (Figure [2F](#F2){ref-type="fig"}), optic nerve (Figure [2G](#F2){ref-type="fig"}) and neural retina (Figure [2H](#F2){ref-type="fig"}). Very weak signal was found to be present in the corneal endothelium (Figure [2B](#F2){ref-type="fig"}) conjunctival epithelium (Figure [2C](#F2){ref-type="fig"}) and neural retina (Nerve fiber layer (NFL), inner nuclear layer, outer plexiform layer, outer nuclear layer and photoreceptors). Stronger signal was identified at the level of the RPE (Figure [2H](#F2){ref-type="fig"}). No expression of LHRH-R was observed in the corneal epithelium (Figure [2A](#F2){ref-type="fig"}) or lens epithelium (Figure [2I](#F2){ref-type="fig"}).

LHRH-R expression was also detected by Western blot in unfixed cadaveric human eye tissues (Figure [11](#F11){ref-type="fig"}). Cadaveric conjunctival, corneal epithelium, retinal, and optic nerve tissue samples were dissected and equal amounts of protein were loaded for each sample. We detected major bands at 42 kD corresponding to LHRH receptor, for all conjunctiva, corneal epithelium, neural retina, and optic nerve tissues. Actin was used for internal control for all samples tested.

Growth hormone releasing hormone and its receptors {#s2_2}
--------------------------------------------------

GHRH (Figure [3](#F3){ref-type="fig"}) and GHRH-R (Figure [4](#F4){ref-type="fig"}) were identified by Immunofluorescence in paraffin-embedded human eyes using anti-GHRH and anti-GHRH-R antibodies.

![Growth hormone releasing hormone (GHRH)](oncotarget-08-66796-g003){#F3}

![Growth hormone releasing hormone receptor (GHRH- R)](oncotarget-08-66796-g004){#F4}

GHRH was found to be expressed in the corneal epithelium (Figure [3A](#F3){ref-type="fig"}), corneal endothelium (Figure [3B](#F3){ref-type="fig"}) conjunctival epithelium (Figure [3C](#F3){ref-type="fig"}), ciliary body non-pigmented epithelium (Figure [3D](#F3){ref-type="fig"}), ciliary body muscle (Figure [3E](#F3){ref-type="fig"}) trabecular meshwork (Figure [3F](#F3){ref-type="fig"}), optic nerve (Figure [3G](#F3){ref-type="fig"}), neural retina (Figure [3H](#F3){ref-type="fig"}) and lens epithelium (Figure [3I](#F3){ref-type="fig"}). GHRH was found to be diffusely expressed throughout all layers of the neural retina with no expression being observed at the level of the RPE (Figure [3H](#F3){ref-type="fig"}).

GHRH-R was found to be expressed in the corneal epithelium (Figure [4A](#F4){ref-type="fig"}), corneal endothelium (Figure [4B](#F4){ref-type="fig"}), conjunctival epithelium (Figure [4C](#F4){ref-type="fig"}), ciliary body non-pigmented epithelium (Figure [4D](#F4){ref-type="fig"}), ciliary body muscle (Figure [4E](#F4){ref-type="fig"}), optic nerve (Figure [4G](#F4){ref-type="fig"}) and neural retina (Figure [4H](#F4){ref-type="fig"}). Weak signal was found to be present in the corneal endothelium (Figure [4B](#F4){ref-type="fig"}) ciliary body muscle (Figure [4F](#F4){ref-type="fig"}), optic nerve (Figure [4G](#F4){ref-type="fig"}), outer plexiform layer, outer nuclear layer and photoreceptors in the neural retina. Stronger signal was identified at the level of the NFL, outer aspect of the inner nuclear layer and RPE. (Figure [4H](#F4){ref-type="fig"}). No expression of GHRH-R was observed in the trabecular meshwork (Figure [4E](#F4){ref-type="fig"}) or lens epithelium. (Figure [4I](#F4){ref-type="fig"}).

Western blot analysis using anti-GHRH-R antibody demonstrated major bands at molecular weight (39.1 kD) corresponding to GHRH-R splice variant-1 (SV-1) in corneal epithelium, neural retina, and optic nerve (Figure [11](#F11){ref-type="fig"}). There was a 50 kD band present in all tissues (conjunctiva, corneal epithelium, neural retina and optic nerve) corresponding to unglycosylated GHRH-R. Additionally, we detected expression for GHRH-R proteins at higher molecular weights (63.7 kD) corresponding to Pituitary Type GHRH receptor (pGHRH-R) in all four tested samples: conjunctiva, corneal epithelium, neural retina, and optic nerve. These major bands correspond to the glycosylated form of the receptor. Actin was used for internal control for all samples tested.

Thyrotropin releasing hormone and its receptor {#s2_3}
----------------------------------------------

TRH (Figure [5](#F5){ref-type="fig"}) and TRH-R (Figure [6](#F6){ref-type="fig"}) were identified by Immunofluorescence in paraffin-embedded human eyes using anti-TRH and anti-TRH-R antibodies.

![Thyrotropin releasing hormone (TRH)](oncotarget-08-66796-g005){#F5}

![Thyrotropin releasing hormone receptor (TRH-R)](oncotarget-08-66796-g006){#F6}

TRH was detected in the corneal epithelium (Figure [5A](#F5){ref-type="fig"}), corneal endothelium (Figure [5B](#F5){ref-type="fig"}), conjunctival epithelium (Figure [5C](#F5){ref-type="fig"}), ciliary body non-pigmented epithelium (Figure [5D](#F5){ref-type="fig"}), ciliary body muscle (Figure [5E](#F5){ref-type="fig"}), trabecular meshwork (Figure [5F](#F5){ref-type="fig"}), optic nerve (Figure [5G](#F5){ref-type="fig"}), neural retina (Figure [5H](#F5){ref-type="fig"}) and lens epithelium (Figure [5I](#F5){ref-type="fig"}). In the neural retina, TRH was found to be expressed in the NFL, inner and outer nuclear layers, inner and outer plexiform layers with stronger immunoreaction in the inner and outer segments of photoreceptors (Figure [5H](#F5){ref-type="fig"}).

TRH-R was found to be expressed in the ciliary body non-pigmented epithelium (Figure [6D](#F6){ref-type="fig"}), ciliary body muscle (Figure [6E](#F6){ref-type="fig"}), optic nerve (Figure [6G](#F6){ref-type="fig"}) and neural retina (Figure [6H](#F6){ref-type="fig"}). No expression was observed in the corneal epithelium (Figure [6A](#F6){ref-type="fig"}), corneal endothelium (Figure [6B](#F6){ref-type="fig"}), conjunctival epithelium (Figure [6C](#F6){ref-type="fig"}) or lens epithelium (Figure [6I](#F6){ref-type="fig"}). Weak signal was detected in the trabecular meshwork (Figure [6F](#F6){ref-type="fig"}). In the neural retina, TRH-R was strongly expressed in the outer nuclear layer and inner segments of photoreceptors (Figure [6H](#F6){ref-type="fig"}).

Western blot was performed on these tissues but no clear signals were obtained for TRH-R (Results not shown).

Somatostatin and its receptor (SST-R1) {#s2_4}
--------------------------------------

Somatostatin hormone (Figure [7](#F7){ref-type="fig"}) and its predominant receptor in the CNS, SST-R1 (Figure [8](#F8){ref-type="fig"}) were identified by Immunofluorescence in paraffin-embedded human eyes using anti-Somatostatin and anti-Somatostatin Receptor 1 antibodies.

![Somatostatin](oncotarget-08-66796-g007){#F7}

![Somatostatin receptor 1(SST-R1)](oncotarget-08-66796-g008){#F8}

Somatostatin was detected in corneal epithelium (Figure [7A](#F7){ref-type="fig"}), corneal endothelium (Figure [7B](#F7){ref-type="fig"}), conjunctival epithelium (Figure [7C](#F7){ref-type="fig"}), ciliary body non-pigmented epithelium (Figure [7D](#F7){ref-type="fig"}), ciliary body muscle (Figure [7E](#F7){ref-type="fig"}), trabecular meshwork (Figure [7F](#F7){ref-type="fig"}), optic nerve (Figure [7G](#F7){ref-type="fig"}), neural retina (Figure [7H](#F7){ref-type="fig"}) and lens epithelium (Figure [7I](#F7){ref-type="fig"}). In the retina, somatostatin was found to be expressed in the NFL, ganglion cell layer, inner and outer nuclear layers, inner and outer plexiform layers and RPE (Figure [7H](#F7){ref-type="fig"}).

SST-R1 was expressed within the corneal epithelium (Figure [8A](#F8){ref-type="fig"}), corneal endothelium (Figure [8B](#F8){ref-type="fig"}), conjunctival epithelium (Figure [8C](#F8){ref-type="fig"}), ciliary body non-pigmented epithelium (Figure [8D](#F8){ref-type="fig"}), ciliary body muscle (Figure [8E](#F8){ref-type="fig"}), trabecular meshwork (Figure [8F](#F8){ref-type="fig"}), optic nerve (Figure [8G](#F8){ref-type="fig"}) and neural retina (Figure [8H](#F8){ref-type="fig"}). No expression was observed in the lens epithelium (Figure [8I](#F8){ref-type="fig"}). In the neural retina, SST-R1 was strongly expressed in the NFL, inner nuclear layer and inner segments of photoreceptors (Figure [8H](#F8){ref-type="fig"}).

SST-R1 expression was also detected by Western blot in cadaveric human eye tissues (Figure [11](#F11){ref-type="fig"}). Cadaveric conjunctival, corneal epithelium, retinal, and optic nerve tissue samples were dissected and equal amounts of protein were loaded for each sample. Major bands were demonstrated at 48 kD corresponding to SST-R1 for all conjunctiva, corneal epithelium, retina, and optic nerve tissues. Actin was used for internal control for all samples tested.

Gastrin releasing peptide and its receptor {#s2_5}
------------------------------------------

GRP (Figure [9](#F9){ref-type="fig"}) and GRP-R/BB2, receptor for GRP/mammalian bombesin, (Figure [10](#F10){ref-type="fig"}) were identified by Immunofluorescence in paraffin-embedded human eyes using anti-GRP and anti-GRP Receptor antibodies.

![Gastrin releasing peptide (GRP)](oncotarget-08-66796-g009){#F9}

![Gastrin releasing peptide receptor (GRP-R)](oncotarget-08-66796-g010){#F10}

![Western blot analysis of neuroendocrine receptor expression in optice nerve, cornea, retina and conjunctiva](oncotarget-08-66796-g011){#F11}

GRP was detected in ciliary body non-pigmented epithelium (Figure [9D](#F9){ref-type="fig"}), retina (Figure [9H](#F9){ref-type="fig"}) and lens epithelium (Figure [9I](#F9){ref-type="fig"}). Weak signal was detected in the ciliary body muscle (Figure [9E](#F9){ref-type="fig"}) and trabecular meshwork (Figure [9F](#F9){ref-type="fig"}). In the neural retina, GRP was found to be strongly and diffusely expressed in the NFL, ganglion cell layer, inner and outer nuclear layers, inner and outer plexiform layers, inner photoreceptor segments and at the level of the RPE (Figure [9H](#F9){ref-type="fig"}). No expression was observed in the corneal epithelium (Figure [9A](#F9){ref-type="fig"}), corneal endothelium (Figure [9B](#F9){ref-type="fig"}), conjunctival epithelium (Figure [9C](#F9){ref-type="fig"}) or optic nerve (Figure [9G](#F9){ref-type="fig"}).

Expression of GRP-R was detected in the corneal epithelium (Figure [10A](#F10){ref-type="fig"}) mostly at the level of basal epithelial layer. GRP-R was also identified in a few cells within the optic nerve substance (Figure [10G](#F10){ref-type="fig"}) and at the level of the ganglion cell layer in the retina (Figure [10H](#F10){ref-type="fig"}) No expression was observed in the corneal endothelium (Figure [10B](#F10){ref-type="fig"}), conjunctival epithelium (Figure [10C](#F10){ref-type="fig"}), ciliary body non-pigmented epithelium (Figure [10D](#F10){ref-type="fig"}), ciliary body muscle (Figure [10E](#F10){ref-type="fig"}), trabecular meshwork (Figure [10F](#F10){ref-type="fig"}) or lens epithelium (Figure [10I](#F10){ref-type="fig"}).

The presence of GRP-R protein was further detected in ocular tissue using Western blot analysis (Figure [6](#F6){ref-type="fig"}). All tissues that were sampled (conjunctiva, corneal epithelium, retina, and optic nerve) showed GRP-R expression with major bands detected at 43 kD corresponding to the GRP receptor. Actin was used for internal control for all samples tested.

Expression of hypothalamic neurohormones and receptor mRNAs in human retina tissue {#s2_6}
----------------------------------------------------------------------------------

Pairs of retinal tissue (right and left) were collected from five pairs of unfixed cadaveric eyes. Samples (*N* = 10) were individually homogenized and mRNA isolated from each. We analyzed each sample, in triplicate, using one-step RT-qPCR with SYBR green chemistry. The expression of each target gene was normalized to the geometric mean of the expression of actβ, β-2M, and GAPDH from the corresponding sample (δδCt method). All retina samples were found to express growth hormone-releasing hormone (GHRH), its receptor (GHRH-R), and a functional splice variant of GHRH-R (SV-1) ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). All samples were also found to express gastrin-releasing peptide (GRP) and its receptor (GRP-R); luteinizing hormone-releasing hormone (LHRH) and its receptor (LHRH-R); somatostatin (SST) and SST receptors 1 and 2 (SST-R1 and SST-R2); and thyrotropin-releasing hormone (TRH) and its receptor (TRH-R) ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Sequences for the target mRNA were obtained using the provided accession number in the NCBI database ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#s3}
==========

The present study systematically demonstrates the expression of LHRH, GHRH, TRH, somatostatin and GRP and their receptors in retinal and extraretinal structures of the human eye, using different techniques, including RT-PCR, Western blot and Immunofluorescence. In addition, we have shown that the expression of these neuroendocrine hormones and their receptors varies throughout different anatomic locations within the eye.

This data may have significant clinical implications by contributing to the better understanding of neuroendocrine influences within the eye. Establishing the presence of hypothalamic hormones and their receptors for each ocular structure also provides a distribution map for these peptides and thereby provides a key for the better understanding of physiologic, pathophysiologic and clinical implications such as the ones that have already been described in the literature \[[@R39], [@R40]\].

Several studies have demonstrated the wide clinical and therapeutic role that these neuropeptides and their receptors may play in various human diseases including cancer, myocardial infarction and pulmonary edema. Analogs of these peptides and their receptors have been used to manipulate the growth of certain tumors such as breast and prostate cancers. New treatment alternatives for patients with cancer may be based on the ability of these analogs to alter the course and progression of the involved tumors.

Previous studies have described the presence and possible effects of TRH and somatostatin in the eye, specifically in the retina, using mouse and other mammalian models including rabbits, cats, and primates. Few studies have demonstrated the presence of these neuropeptides in the human retina using techniques other than immunofluorescence. To our knowledge, this is the first time that immunofluorescence studies have been used to demonstrate the presence of LHRH, GHRH, TRH, somatostatin, GRP and their receptors, using formalin fixed paraffin embedded tissue, in the human eye. Minor differences were found between the results obtained from RT-PCR, Western blot and Immunofluorescence for the expression of LHRH, GHRH, Somatostatin, GRP and their receptors. No clear band or positive signal was identified using the Western blot technique for TRH receptor. However, RT-PCR and immunofluorescence demonstrated its presence in the neural retina and optic nerve.

These techniques may help to evaluate and characterize the presence of these peptides and their role in other ophthalmic diseases such as Ocular Surface Squamous Neoplasia (OSSN), intraocular tumors and diabetic retinopathy, among others. These neuropeptides may play a significant role in multiple ocular physiologic mechanisms, including regulatory roles in ocular surface homeostasis, secretion or absorption of aqueous humor, and function of retinal fiber layer, ganglion cell layer, photoreceptor and optic nerve, amongst others. The use of synthetic neuropeptide analogs that have been developed to treat a number of diseases \[[@R40]-[@R41]) may now be extended, with appropriate preliminary clinical evaluation, to patients with ophthalmic diseases, given that we have shown that hypothalamic target receptors exist throughout the eye. Previous studies have demonstrated that the localization, distribution and expression pattern of these receptors and their subtypes may differ depending on the pathology present and the targeted tissue \[[@R46], [@R47]\], however, these have generally been disease specific. Our findings support the merit of further verification, elucidation, and mapping of the distribution of these neuropeptides and their respective receptors to further delineate the role that analogs of these hormonal peptides may play in models of various eye diseases.

MATERIALS AND METHODS {#s4}
=====================

This study was approved by the Institutional Review Board (IRB) at the University of Miami, Miller School of Medicine.

Immunofluorescence staining protocol {#s4_1}
------------------------------------

Two formalin-fixed paraffin embedded eyes, from patients without any clinical history of intraocular disease and having no histological evidence of intraocular pathology, were selected from the Florida Lions Ocular Pathology Laboratory archives. Four-micron sections were cut from the paraffin embedded blocks. Slides were de-paraffinized and rehydrated with xylene and graded series of ethanol. Antigen retrieval was performed with Trilogy antigen retrieval solution (Cell Marque, Rocklin, California) and subsequently washed in 0.5% Triton and PBS. Blocking was performed with Background Terminator (Biocare Medical, Concord, California). The following primary polyclonal antibodies (Abcam) were used: Anti-LHRH antibody (ab5617) Anti-LHRH Receptor antibody (ab183079), Anti-GHRH antibody (ab8899), Anti-GHRH Receptor antibody (ab76263), Anti-TRH antibody (ab174714), Anti-TRH Receptor antibody (ab151510), Anti-somatostatin antibody (ab183855), Anti-somatostatin Receptor-1 antibody (ab2366), Anti-GRP antibody (ab202123) and Anti-GRP Receptor antibody (ab188821). Primary antibody was diluted in 0.5% Triton and PBS and left overnight at 4°C. After washing, the sections were incubated with the secondary antibody for 120 minutes. Alexa Fluor 488 (ab150077) was used with Anti-LHRH antibody, Anti-GHRH antibody, Anti-TRH antibody, Anti-GRP antibody and Anti-somatostatin antibody. Cy5 (ab97077) was used with Anti-LHRH Receptor antibody, Anti-GHRH Receptor antibody, Anti-TRH Receptor antibody, Anti-GRP Receptor antibody and Anti-somatostatin Receptor-1 antibody. Slides were then rinsed in PBS, mounted in Vectashield (Vector Laboratories) and sealed with clear nail varnish. Stained slides were stored at 4°C. Sections were visualized with a Leica confocal scanning microscope. Negative control assays were performed by omission of the primary antibodies. Null staining of these negative control sections confirmed the specificity of the staining (Data not shown).

Western blot analysis {#s4_2}
---------------------

Cadaveric human eyes were obtained from the Florida Lions Eye Bank within 48 hours of death. Only deceased subjects without documented history of ophthalmic diseases or ophthalmic surgery were considered. Eyes were dissected and conjunctival tissue, corneal epithelium, retinal tissue, and optic nerve substance were isolated and snap frozen in dry ice.

For Western blot (WB) analysis, equal amounts of protein were loaded for all samples. Actin was run as an internal control for all samples. The following antibodies were utilized for WB assays: LHRH-R (Abcam ab-58561), GHRH-R/SV1 (Abcam ab28692), GRP-R (Santa Cruz sc-26836), SST-R1 (Santa Cruz sc-25675), and Actin (Sigma A5441).

SYBR green-based RT-PCR primer design {#s4_3}
-------------------------------------

Gene expression was determined using qRT-PCR. All RNA targets were analyzed using custom designed oligonucleotide primers designed for use in SYBR green (ThermoFisher Scientific, Waltham, MA)based qRT-PCR. The assays were designed using extremely strict parameters in order to exclude non-human templates and target regions of low energy secondary structures, thus maximizing both specificity and sensitivity. All assays were determined to produce a single product, which was verified as the human target of interest by DNA sequencing.

Transcript specific primers were designed using the Beacon Designer software suite (PREMIER Biosoft, Palo Alto, California) with modified parameters. Primer searches were limited to regions on mRNA sequences (Refseqs), which were not homologous to the equivalent mRNA from mice (*Mus musculus*). The resulting human-specific sequences were screened for regions of stable secondary structures (∆G \< −3.0 Kcal/mol), which were excluded from our primer search. Primer searches were optimized for reverse transcription at 52°C and fast cycling PCR with single step annealing/extension at 57°C. Primer hairpin energy was limited to ∆G = −3.0 Kcal/mol; dimer energies were limited to ∆G = −4.0 Kcal/mol. Dimers including the last 3 bases of the 3' end of the primer were limited to ∆G = −2.0 Kcal/mol. Primers were designed to result in amplicons of 75-200 bp in length. Primer pairs that were less than 98% efficient were excluded. All primers used produce a single product of predictable and reproducible melting temperature (Tm). All primers were optimized and verified by sequencing the corresponding amplicons.

Real-time quantitative reverse-transcription polymerase chain reaction (qRT PCR) {#s4_4}
--------------------------------------------------------------------------------

Gene expression analysis was conducted using one-step qRT-PCR with SYBR green chemistry. This method conducts the reverse transcription reaction and PCR in a single tube format from 20ng total RNA template. The production of the PCR amplified gene product is monitored using the fluorescence resulting from the binding of SYBR green to the double stranded DNA amplicons. Reactions were conducted in a CFX96 Real-Time System using the One-Step SYBR Green qRT-PCR reaction kit (Bio-Rad, Hercules, California). Reactions were conducted in triplicate and normalized to three internal standard genes using the δδCt method.
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